IntroductionWith increased life expectancy, the desire to look younger has increased. Hence, many patients approach dermatologists for antiaging treatment. However, data regarding management of skin aging in India are scarce.AimsTo understand management patterns for skin aging among dermatologists in India.MethodsOverall, 147 Indian dermatologists were administered a questionnaire‐based survey about patient characteristics, signs of skin aging, treatment options, and cost.ResultsAmong all the patients coming for dermatologists' consultation, 10%‐40% were for antiaging treatment. About 70% dermatologists opined that majority of patients aged 30‐40 years consulted for antiaging treatment, and the male to female ratio was 3:7. Approximately 46% of dermatologists felt that antiaging treatment should be initiated by the age of 30. Common signs of aging were wrinkles, pigmentation, dull skin or complexion, and dry skin. Based on patient's age and sex, dermatologists prescribed a combination of 2‐4 products, which included antioxidants, retinoids, growth factors, and moisturizers. Improvement was assessed by photographic and clinical evaluation, and by patients' satisfaction (55%). Effect of the antiaging products was evident within 4‐6 months. Earliest improvement was noted in dry skin and dull complexion. Average extent of improvement noted by 6 months was approximately 20%‐30%. The average monthly expenditure on antiaging treatments was 2000‐4000 INR.ConclusionBoth men and women seek clinical treatment for skin aging in India. Dermatologists prescribe a combination of 2‐4 products, including antioxidants, retinoids, growth factors, and moisturizers. Available antiaging therapies show an average improvement of up to 30% by 6 months.

No abstract

Background: Moisturizers are recommended as an adjuvant to acne therapies especially topical/systemic retinoids to counteract their cutaneous side-effects. Moisturisers also reduce inflammation and the intensity of acne. The compliment study was designed to evaluate effectiveness and tolerability of moisturiser (Excela, Cipla Ltd., Mumbai, India) in patients prescribed isotretinoin for managing their acne in real-world scenario. Methods: This open-label, observational, prospective, non-comparative multicentre study was conducted between June 2019 and January 2020. Patients who were prescribed Excela moisturiser as an adjuvant to isotretinoin for acne management were enrolled. After four weeks, the investigator graded the patient’s skin on smoothness and softness on a five-point scale and dryness, scaling and redness on a four-point scale. Its organoleptic characteristics and tolerability were evaluated using the subject assessment questionnaire. Results: We enrolled 200 patients (average age: 24.02±5.44 years). Investigators rated smoothness and softness of the skin as very good to excellent in 129 (64.5%) and 113 (56.5%) patients. No patient reported severe skin dryness, scaling or redness. Very good to excellent spreadability and appeal was rated by 132 (66.0%) and 133 (66.5%) patients, respectively. Eighty (40%) patients rated the moisturiser as non-greasy/non-sticky. Itching (1%), redness (0.5%), cold (0.5%), and cough (0.5%) were reported as adverse events but were of mild intensity and unrelated to the study product. No patient experienced serious adverse event or moisturiser-related adverse event. Conclusions: Overall, Excela moisturiser was effective and tolerable in patients with acne who were prescribed isotretinoin at the end of 4-week-long treatment period.